BRIEF-Gossamer Bio And Chiesi Group Announce Transformative Global Collaboration To Develop And Commercialize Seralutinib In PAH, PH-ILD & Other Indications

Reuters05-06

May 6 (Reuters) - Gossamer Bio Inc :

* GOSSAMER BIO AND CHIESI GROUP ANNOUNCE TRANSFORMATIVE GLOBAL COLLABORATION TO DEVELOP AND COMMERCIALIZE SERALUTINIB IN PAH, PH-ILD & OTHER INDICATIONS

* GOSSAMER BIO INC: GOSSAMER TO RECEIVE $160 MILLION DEVELOPMENT REIMBURSEMENT PAYMENT

* GOSSAMER BIO INC: ELIGIBLE TO RECEIVE UP TO $146 MILLION IN REGULATORY AND $180 MILLION IN SALES MILESTONES

* GOSSAMER BIO INC: GOSSAMER AND CHIESI PLAN TO INITIATE PHASE 3 TRIAL OF SERALUTINIB IN PH-ILD IN MID-2025

* GOSSAMER BIO INC: WILL CONTINUE TO LEAD GLOBAL DEVELOPMENT OF SERALUTINIB IN PAH AND PH-ILD

* GOSSAMER BIO INC: IN US, COMPANIES WILL EVENLY SHARE COMMERCIAL PROFITS AND LOSSES

* GOSSAMER BIO INC: CHIESI WILL HAVE EXCLUSIVE RIGHT TO COMMERCIALIZE SERALUTINIB OUTSIDE OF US

Source text for Eikon: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2433429237?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-05-06 19:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2433429237","market":"us","top_or_hot":-1,"title":"BRIEF-Gossamer Bio And Chiesi Group Announce Transformative Global Collaboration To Develop And Commercialize Seralutinib In PAH, PH-ILD & Other Indications","media":"Reuters","content":"<html><body><p>May 6 (Reuters) - Gossamer Bio Inc   :</p><p>   * GOSSAMER BIO AND CHIESI GROUP ANNOUNCE TRANSFORMATIVE GLOBAL COLLABORATION TO DEVELOP AND COMMERCIALIZE SERALUTINIB IN PAH, PH-ILD &amp; OTHER INDICATIONS</p><p>   * GOSSAMER BIO INC: GOSSAMER TO RECEIVE $160 MILLION DEVELOPMENT REIMBURSEMENT PAYMENT</p><p>   * GOSSAMER BIO INC: ELIGIBLE TO RECEIVE UP TO $146 MILLION IN REGULATORY AND $180 MILLION IN SALES MILESTONES</p><p>   * GOSSAMER BIO INC: GOSSAMER AND CHIESI PLAN TO INITIATE PHASE 3 TRIAL OF SERALUTINIB IN PH-ILD IN MID-2025</p><p>   * GOSSAMER BIO INC: WILL CONTINUE TO LEAD GLOBAL DEVELOPMENT OF SERALUTINIB IN PAH AND PH-ILD</p><p>   * GOSSAMER BIO INC: IN US, COMPANIES WILL EVENLY SHARE COMMERCIAL PROFITS AND LOSSES</p><p>   * GOSSAMER BIO INC: CHIESI WILL HAVE EXCLUSIVE RIGHT TO COMMERCIALIZE SERALUTINIB OUTSIDE OF US</p><p>Source text for Eikon:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Gossamer Bio And Chiesi Group Announce Transformative Global Collaboration To Develop And Commercialize Seralutinib In PAH, PH-ILD & Other Indications</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Gossamer Bio And Chiesi Group Announce Transformative Global Collaboration To Develop And Commercialize Seralutinib In PAH, PH-ILD & Other Indications\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-05-06 19:32 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>May 6 (Reuters) - Gossamer Bio Inc   :   * GOSSAMER BIO AND CHIESI GROUP ANNOUNCE TRANSFORMATIVE GLOBAL COLLABORATION TO DEVELOP AND COMMERCIALIZE SERALUTINIB IN PAH, PH-ILD & OTHER INDICATIONS   * ...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0320765489.SGD","symbol_name":"FTIF - Franklin Mutual US Value A Acc SGD","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2433429237","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2433429237","pubTimestamp":1714995129,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"May 6  - Gossamer Bio Inc   :   * GOSSAMER BIO AND CHIESI GROUP ANNOUNCE TRANSFORMATIVE GLOBAL COLLABORATION TO DEVELOP AND COMMERCIALIZE SERALUTINIB IN PAH, PH-ILD & OTHER INDICATIONS   * GOSSAMER BIO INC: GOSSAMER TO RECEIVE $160 MILLION DEVELOPMENT REIMBURSEMENT PAYMENT   * GOSSAMER BIO INC: ELIGIBLE TO RECEIVE UP TO $146 MILLION IN REGULATORY AND $180 MILLION IN SALES MILESTONES   * GOSSAMER BIO INC: GOSSAMER AND CHIESI PLAN TO INITIATE PHASE 3 TRIAL OF SERALUTINIB IN PH-ILD IN MID-2025   * GOSSAMER BIO INC: WILL CONTINUE TO LEAD GLOBAL DEVELOPMENT OF SERALUTINIB IN PAH AND PH-ILD   * GOSSAMER BIO INC: IN US, COMPANIES WILL EVENLY SHARE COMMERCIAL PROFITS AND LOSSES   * GOSSAMER BIO INC: CHIESI WILL HAVE EXCLUSIVE RIGHT TO COMMERCIALIZE SERALUTINIB OUTSIDE OF USSource text for Eikon:    Further company coverage:    ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0320765489.SGD":"FTIF - Franklin Mutual US Value A Acc SGD","BK4505":"高瓴资本持仓","BK4585":"ETF&股票定投概念","GOSS":"Gossamer Bio Inc.","BK4139":"生物科技","PH":"汉尼汾","LU0070302665.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) ACC","BK4588":"碎股","BK4580":"工业 4.0","BK4161":"工业机械","LU0211331839.USD":"FRANKLIN MUTUAL GLB DISCOVERY \"A\" (USD) ACC","LU1989772840.SGD":"CPR Invest - Climate Action A2 Acc SGD-H","LU0208291251.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) INC","LU1989772923.USD":"CPR Invest - Climate Action A2 Acc USD-H"},"translate_title":"简介——Gossamer Bio和Chiesi集团宣布在PAH、PH-ILD和其他适应症中开发和商业化Seralutinib的变革性全球合作","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PH":1,"GOSS":0.9},"content_text":"May 6 (Reuters) - Gossamer Bio Inc   :   * GOSSAMER BIO AND CHIESI GROUP ANNOUNCE TRANSFORMATIVE GLOBAL COLLABORATION TO DEVELOP AND COMMERCIALIZE SERALUTINIB IN PAH, PH-ILD & OTHER INDICATIONS   * GOSSAMER BIO INC: GOSSAMER TO RECEIVE $160 MILLION DEVELOPMENT REIMBURSEMENT PAYMENT   * GOSSAMER BIO INC: ELIGIBLE TO RECEIVE UP TO $146 MILLION IN REGULATORY AND $180 MILLION IN SALES MILESTONES   * GOSSAMER BIO INC: GOSSAMER AND CHIESI PLAN TO INITIATE PHASE 3 TRIAL OF SERALUTINIB IN PH-ILD IN MID-2025   * GOSSAMER BIO INC: WILL CONTINUE TO LEAD GLOBAL DEVELOPMENT OF SERALUTINIB IN PAH AND PH-ILD   * GOSSAMER BIO INC: IN US, COMPANIES WILL EVENLY SHARE COMMERCIAL PROFITS AND LOSSES   * GOSSAMER BIO INC: CHIESI WILL HAVE EXCLUSIVE RIGHT TO COMMERCIALIZE SERALUTINIB OUTSIDE OF USSource text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.5","shortVersion":"4.22.5","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2433429237"}